AKT1 and colonic neoplasm: To test the therapeutic potential of the finding that reactivation of ERK and Akt is responsible for resistance of mutant BRAF colon cancer cells to AUY922, we treated RKO and WiDr cells grown in 3-dimensional cultures with AUY922 in the presence or absence of the BRAF inhibitor PLX4720 or the PI3K inhibitor LY294002.